Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Almost all patients with multiple myeloma (MM) will eventually develop disease that has
relapsed with or become refractory to available treatments and will require additional …

Background Isatuximab is an anti-CD38 monoclonal antibody approved in combination with
pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory …

Background Belantamab mafodotin had single-agent activity in patients with relapsed or
refractory multiple myeloma, a finding that supports further evaluation of the agent in …

PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months),
daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged …

PURPOSE In the phase II ELOQUENT-3 trial (ClinicalTrials. gov identifier: NCT02654132),
elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved …

Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with
carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA …

We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma
(RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using …

Acute kidney injury (AKI) is common in patients with cancer, especially in those with
haematological malignancies. Kidney injury might be a direct consequence of the …

PURPOSE With the initial analysis of POLLUX at a median follow-up of 13.5 months,
daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly …